CryoCell Net Income from 2010 to 2026
| CCEL Stock | USD 3.43 0.06 1.78% |
Net Income | First Reported 1996-02-29 | Previous Quarter 355.8 K | Current Value 1.6 M | Quarterly Volatility 1.6 M |
Check CryoCell International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CryoCell International's main balance sheet or income statement drivers, such as Depreciation And Amortization of 625.6 K, Selling General Administrative of 11.5 M or Total Revenue of 18.9 M, as well as many indicators such as Price To Sales Ratio of 2.41, Dividend Yield of 0.0245 or Days Sales Outstanding of 79.7. CryoCell financial statements analysis is a perfect complement when working with CryoCell International Valuation or Volatility modules.
CryoCell | Net Income | Build AI portfolio with CryoCell Stock |
Historical Net Income data for CryoCell International serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether CryoCell International represents a compelling investment opportunity.
Latest CryoCell International's Net Income Growth Pattern
Below is the plot of the Net Income of CryoCell International over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CryoCell International financial statement analysis. It represents the amount of money remaining after all of CryoCell International operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CryoCell International's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CryoCell International's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 402.1 K | 10 Years Trend |
|
Net Income |
| Timeline |
CryoCell Net Income Regression Statistics
| Arithmetic Mean | 359,951 | |
| Geometric Mean | 1,193,353 | |
| Coefficient Of Variation | 1,062 | |
| Mean Deviation | 2,326,833 | |
| Median | 485,530 | |
| Standard Deviation | 3,821,415 | |
| Sample Variance | 14.6T | |
| Range | 17.6M | |
| R-Value | (0.02) | |
| Mean Square Error | 15.6T | |
| R-Squared | 0.0004 | |
| Significance | 0.94 | |
| Slope | (15,315) | |
| Total Sum of Squares | 233.7T |
CryoCell Net Income History
Other Fundumenentals of CryoCell International
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
CryoCell International Net Income component correlations
About CryoCell International Financial Statements
CryoCell International investors utilize fundamental indicators, such as Net Income, to predict how CryoCell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income | 462.4 K | 485.5 K | |
| Net Income Applicable To Common Shares | 3.2 M | 2.1 M | |
| Net Income From Continuing Ops | 361.9 K | 698.5 K | |
| Net Income Per Share | 0.04 | 0.05 | |
| Net Income Per E B T | 0.14 | 0.16 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of CryoCell International Correlation against competitors. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. Projected growth potential of CryoCell fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CryoCell International assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.31) | Dividend Share 0.65 | Earnings Share (0.06) | Revenue Per Share | Quarterly Revenue Growth (0.03) |
Investors evaluate CryoCell International using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CryoCell International's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause CryoCell International's market price to deviate significantly from intrinsic value.
It's important to distinguish between CryoCell International's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CryoCell International should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CryoCell International's market price signifies the transaction level at which participants voluntarily complete trades.